Cue Biopharma (NASDAQ:CUE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• Cue Biopharma reported a quarterly earnings per share of ($0.09), exceeding estimates by $0.04.
• The company’s revenue for the quarter was $2.95 million, surpassing analyst projections of $2.00 million.
• Hedge fund Northwestern Mutual Wealth Management Co. increased its stake in Cue Biopharma by 730%, now owning 83,000 shares.

Cue Biopharma (NASDAQ:CUE - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.04, Zacks reports. Cue Biopharma had a negative net margin of 469.35% and a negative return on equity of 230.13%. The company had revenue of $2.95 million during the quarter, compared to analyst estimates of $2.00 million.

Cue Biopharma Stock Down 3.8%

Shares of Cue Biopharma stock traded down $0.03 during trading on Monday, hitting $0.80. The company's stock had a trading volume of 29,604 shares, compared to its average volume of 260,342. Cue Biopharma has a 52 week low of $0.45 and a 52 week high of $1.99. The company has a market capitalization of $61.10 million, a PE ratio of -1.42 and a beta of 1.53. The company has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $0.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.60.

Institutional Investors Weigh In On Cue Biopharma

A hedge fund recently raised its stake in Cue Biopharma stock. Northwestern Mutual Wealth Management Co. boosted its holdings in Cue Biopharma, Inc. (NASDAQ:CUE - Free Report) by 730.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 83,000 shares of the company's stock after buying an additional 73,000 shares during the quarter. Northwestern Mutual Wealth Management Co. owned 0.11% of Cue Biopharma worth $57,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.04% of the company's stock.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.